STOCK TITAN

Adial Pharmaceuticals Inc - ADIL STOCK NEWS

Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.

Adial Pharmaceuticals Inc (ADIL) is a clinical-stage biopharmaceutical company pioneering personalized treatments for alcohol use disorder through advanced pharmacogenomics. This page provides investors and healthcare professionals with essential updates on ADIL's clinical trials, regulatory milestones, and strategic initiatives.

Access timely announcements about the company's lead investigational drug AD04—a serotonin-3 receptor antagonist designed for genetically identified patient groups. Stay informed about clinical study results, FDA communications, intellectual property developments, and partnership opportunities that demonstrate ADIL's progress in addiction medicine.

Key updates include progress reports on the 505(b)(2) regulatory pathway, companion diagnostic advancements, and peer-reviewed research publications. All content is curated to help stakeholders track the company's evidence-based approach to treating addictive disorders through precision medicine.

Bookmark this page for direct access to primary source materials and analysis-free reporting on ADIL's scientific and corporate developments. Check regularly for new filings, trial data disclosures, and strategic announcements that shape the company's trajectory in biopharmaceutical innovation.

Rhea-AI Summary
Adial Pharmaceuticals receives Best Practices Technology Innovation Leadership Award in precision medicine for addiction disorders industry
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
none
-
Rhea-AI Summary
Pre-registration for Adial Pharmaceuticals' LinkedIn Live event discussing non-abstinence-based therapies in Alcohol Use Disorder (AUD) begins on September 28th. The event will feature industry experts Joseph Volpicelli and Jonathan Hunt-Glassman, and will be moderated by Kemp Dolliver. The webinar aims to address the current treatment landscape and the need for non-abstinence-based therapeutics. The event will take place on October 4th at 2:15 p.m. ET, with a replay available afterwards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.79%
Tags
conferences
-
Rhea-AI Summary
Adial Pharmaceuticals CEO to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
conferences
Rhea-AI Summary
Adial Pharmaceuticals to present at ESBRA conference on new approaches in the treatment of Alcohol Use Disorder (AUD) through precision medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
none
-
Rhea-AI Summary
Adial Pharmaceuticals regains compliance with Nasdaq listing rules
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.34%
Tags
none
-
Rhea-AI Summary
Adial Pharmaceuticals reports positive feedback from regulatory meetings and significant reduction in cash burn rate
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
Rhea-AI Summary
Adial Pharmaceuticals announces a 1-for-25 reverse stock split of its common stock, effective August 4, 2023. The split will reduce outstanding shares from 30.5 million to 1.2 million. The reverse split aims to bring the company into compliance with Nasdaq's minimum bid price requirement and attract a broader group of investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
none
-
Rhea-AI Summary
Adial Pharmaceuticals provides an update on its clinical development plan for AD04, a treatment for Alcohol Use Disorder. The company received positive feedback from regulators and plans to focus on the US market. They will conduct two Phase 3 trials to support potential approval, with a total cost of approximately $25 million. AD04 is expected to be registered with the FDA in Q3 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
95%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
conferences
Rhea-AI Summary
Adial Pharmaceuticals provides business update and financial results for Q1 2023. The company conducted meetings with regulatory agencies and received upfront cash from the sale of Purnovate assets. They also engaged The Keswick Group for partnering efforts. Adial closed a registered direct offering and ended Q1 with $2.3 million in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
Adial Pharmaceuticals Inc

Nasdaq:ADIL

ADIL Rankings

ADIL Stock Data

4.51M
6.48M
1.75%
9.58%
10.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
CHARLOTTESVILLE